ANI Pharmaceuticals (ANIP) Receives a Buy from Raymond James

In a report released today, Elliot Wilbur from Raymond James maintained a Buy rating on ANI Pharmaceuticals (ANIPResearch Report), with a price target of $48.00. The company’s shares closed yesterday at $34.87.

Wilbur covers the Healthcare sector, focusing on stocks such as Perrigo Company, Teva Pharmaceutical, and ANI Pharmaceuticals. According to TipRanks, Wilbur has an average return of -9.4% and a 36.11% success rate on recommended stocks.

ANI Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $48.00.

See the top stocks recommended by analysts >>

ANIP market cap is currently $601.4M and has a P/E ratio of -8.16.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Read More on ANIP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More